Bacteriophage-based vaccines and engineered bacteriophage
US11826421B2 · kind B2 · utility
0Cited by
2References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 18, 2021 |
| Grant date | Nov 28, 2023 |
| Priority date | — |
| Expiry date | Feb 16, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Engineered bacteriophage and methods of forming the bacteriophage are described. Multivalent bacteriophage are described that can include multiple different exogenous polypeptides at a surface of the capsid head. Vaccines and methods of forming and using vaccines are described. A vaccine can include an engineered bacteriophage that exhibits an immunogenic exogenous polypeptide at a surface of the bacteriophage. Multivalent bacteriophage and immunogenic bacteriophage are free of nucleic acids encoding the exogenous polypeptide(s).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.